Want to see SONVY full AI Analyst Report?
SONVY Stock Chart & Stats
$52.91
-$0.29(-0.44%)
At close: 4:00 PM EST
$52.91
-$0.29(-0.44%)
Day’s Range― - ―
52-Week Range$42.66 - $60.66
Previous CloseN/A
Volume1.17K
Average Volume (3M)3.58K
Market Cap
$14.63B
Enterprise Value$12.74B
Total Cash (Recent Filing)$722.10M
Total Debt (Recent Filing)$1.71B
Price to Earnings (P/E)27.9
Beta0.82
Next Earnings
Nov 12, 2026EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend Yield2.08%
Share Statistics
EPS (TTM)1.81
Shares Outstanding298,134,030
10 Day Avg. Volume2,397
30 Day Avg. Volume3,581
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)4.16
Price to Sales (P/S)3.01
P/FCF Ratio17.20
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit4.92
Enterprise Value/Ebitda13.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.68
Revenue Forecast (FY)$4.82B
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsSonova’s consistently very high gross and EBITDA margins reflect durable pricing power, favorable product mix, and scale in hearing instruments. High margins support reinvestment into R&D, marketing and service networks, and provide resilience through cycles and pricing pressures.
Strong Cash Generation And Capital EfficiencyConsistent FCF conversion and high ROCE create lasting financial flexibility for dividends, bolt-on M&A and product investment. Even with recent FCF cooling, persistent positive cash flow underpins disciplined capital allocation and supports strategy execution over the medium term.
Product-led Market Share Gains And Multi-channel GrowthNew devices (Virto R, Infinio Ultra, AI features) and strong wholesale momentum drive recurring revenue and market share. Combined retail expansion and multi-channel distribution broaden addressable markets and create durable competitive advantages via product differentiation and direct customer relationships.
Bears Say
Cochlear Implants Weakness And China DisruptionAdvanced Bionics faces structural headwinds: pricing/procurement changes in China and new competitor products have materially reduced volumes and margins. Recovery depends on a planned processor launch and regulatory timing, introducing execution and market-access risk to medium‑term earnings.
Recent Top-line Softness And Cash Flow CoolingA recent drop in revenue, margin compression and a meaningful fall in FCF indicate choppier growth and weaker operational leverage. If sustained, this trend can limit reinvestment capacity, constrain margin recovery initiatives and reduce the buffer for cyclical or competitive pressures.
Material One-off Charges And FX HeadwindsSignificant non-recurring charges and large FX translation hits have reduced reported profitability and add uncertainty to near-term cash outcomes. These headwinds complicate earnings comparability and can blunt reported margin improvement even if underlying operations improve.
Sonova Holding AG News
SONVY FAQ
What was Sonova Holding AG Unsponsored ADR’s price range in the past 12 months?
Sonova Holding AG Unsponsored ADR lowest stock price was $42.66 and its highest was $60.66 in the past 12 months.
What is Sonova Holding AG Unsponsored ADR’s market cap?
Sonova Holding AG Unsponsored ADR’s market cap is $14.63B.
When is Sonova Holding AG Unsponsored ADR’s upcoming earnings report date?
Sonova Holding AG Unsponsored ADR’s upcoming earnings report date is Nov 12, 2026 which is in 130 days.
How were Sonova Holding AG Unsponsored ADR’s earnings last quarter?
Sonova Holding AG Unsponsored ADR released its earnings results on May 18, 2026. The company reported $1.439 earnings per share for the quarter, beating the consensus estimate of $1.438 by $0.001.
Is Sonova Holding AG Unsponsored ADR overvalued?
According to Wall Street analysts Sonova Holding AG Unsponsored ADR’s price is currently Overvalued.
Does Sonova Holding AG Unsponsored ADR pay dividends?
Sonova Holding AG Unsponsored ADR pays a Annually dividend of $1.16 which represents an annual dividend yield of 2.08%. See more information on Sonova Holding AG Unsponsored ADR dividends here
What is Sonova Holding AG Unsponsored ADR’s EPS estimate?
Sonova Holding AG Unsponsored ADR’s EPS estimate is 1.11.
How many shares outstanding does Sonova Holding AG Unsponsored ADR have?
Sonova Holding AG Unsponsored ADR has 298,134,030 shares outstanding.
What happened to Sonova Holding AG Unsponsored ADR’s price movement after its last earnings report?
Sonova Holding AG Unsponsored ADR reported an EPS of $1.439 in its last earnings report, beating expectations of $1.438. Following the earnings report the stock price went up 7.936%.
Which hedge fund is a major shareholder of Sonova Holding AG Unsponsored ADR?
Currently, no hedge funds are holding shares in SONVY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sonova Holding AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.09%
12-Months-Change
Fundamentals
Return on Equity
21.52%
Trailing 12-Months
Asset Growth
4.61%
Trailing 12-Months
Company Description
Sonova Holding AG Unsponsored ADR
Sonova Holding AG is a prominent developer, manufacturer, and global distributor of hearing health solutions for all age groups. The company's operations are divided into two core areas: Hearing Instruments and Cochlear Implants. Its product range includes sophisticated wireless communication devices, innovative rechargeable hearing aids, and a comprehensive selection of consumer audio electronics such as wireless headsets, hearables designed for speech enhancement, high-fidelity headphones, microphones, and wireless transmission systems. Furthermore, Sonova offers extensive audiological care services. Key brands under its umbrella include Phonak, Unitron, and Hansaton for hearing instruments; Advanced Bionics for cochlear implants; and Sennheiser for consumer audio. Its audiological care services are delivered through a vast network of approximately 3,600 retail locations and clinics, known by various regional names including AudioNova, Audium, and Connect Hearing. Sonova distributes its products through independent partners and provides services via its direct network. The company maintains a significant international presence, operating in the United States, Europe, the Middle East, Africa, and the Asia Pacific region. Established in Stäfa, Switzerland, in 1947, the firm was formerly known as Phonak Holding AG before adopting its current name, Sonova Holding AG, in August 2007.
SONVY Company Deck
SONVY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong product-led sales momentum (notably in wholesale and select APAC markets), meaningful operating leverage, high cash conversion and disciplined capital allocation. Key short-term challenges are concentrated in the Cochlear Implants business (notably China) and several non‑core one-off charges plus FX headwinds. Management provided a confident but execution‑sensitive midterm roadmap (innovation, multi-channel expansion, operational savings) and reiterated growth and margin guidance for FY26/27.View all SONVY earnings summariesTechnical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---